Intercept Pharmaceuticals (ICPT) Receives News Impact Rating of 0.12
News headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have trended somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.6381898611919 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases (seekingalpha.com)
- Interesting ICPT Put And Call Options For June 2019 (nasdaq.com)
- Intercept Pharmaceuticals: Buyout Speculation Stokes Shares (seekingalpha.com)
- Ignoring these stocks can haunt investors for years to come: ACADIA Pharmaceuticals Inc. (ACAD), Intercept … (fintelegraph.com)
- Analyze Stock Volatility of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) (finherald.com)
Shares of Intercept Pharmaceuticals opened at $80.56 on Wednesday, MarketBeat Ratings reports. The company has a debt-to-equity ratio of -6.88, a current ratio of 4.58 and a quick ratio of 4.58. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $135.59. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -5.60 and a beta of -1.78.
A number of equities analysts recently commented on the company. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 2nd. Wedbush decreased their price target on Intercept Pharmaceuticals from $203.00 to $256.00 and set an “outperform” rating for the company in a research note on Tuesday, April 17th. Cowen reiterated a “buy” rating and issued a $88.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday, May 9th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $58.00 price target on shares of Intercept Pharmaceuticals in a research note on Tuesday, May 8th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $125.05.
In related news, CEO Mark Pruzanski bought 7,812 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was bought at an average cost of $64.00 per share, for a total transaction of $499,968.00. Following the completion of the purchase, the chief executive officer now directly owns 11,642 shares in the company, valued at approximately $745,088. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Keith Michael Gottesdiener bought 1,171 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was bought at an average price of $64.00 per share, with a total value of $74,944.00. Following the completion of the purchase, the director now owns 5,001 shares of the company’s stock, valued at $320,064. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 399,608 shares of company stock valued at $25,574,912. 4.90% of the stock is currently owned by insiders.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.